Becton, Dickinson and Company

NYSE:BDX

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 48.98 B

Share Price

USD 169.97

Avg Daily Volume

2,902,763

Change (1 day)

-0.54%

Change (1 year)

-26.62%

Change (YTD)

-25.08%

Becton, Dickinson and Company Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 1.29

Becton, Dickinson and Company Current Ratio is 1.29 for the Trailing 12 Months (TTM) ending March 31, 2025, a 2.70% change year over year. Current ratio represents the short-term liquidity measurement, showing current assets' coverage of liabilities. Higher ratio implies better ability to meet short-term obligations.

Becton, Dickinson and Company Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 1.26, a 5.97% change year over year.
Becton, Dickinson and Company Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 1.19, a -10.39% change year over year.
Becton, Dickinson and Company Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 1.33, a -13.70% change year over year.
Becton, Dickinson and Company Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 1.54, a 47.76% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Current Ratio	Interest Coverage Ratio	Return on Capital Employed (ROCE)	Return on Equity (ROE)

NYSE: BDX

Becton, Dickinson and Company

CEO	Mr. Thomas E. Polen Jr.
IPO Date	Feb. 21, 1973
Location	United States
Headquarters	1 Becton Drive
Employees	70,000
Sector	🏥 Health Care
Industries Medical Instruments 🧬 Biotechnology 🔬 Clinical Trials

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.